ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial

Background: ABX464 (obefazimod) is a small molecule that upregulates a single microRNA (miR-124) in immune cells and reduces the production of various inflammatory cytokines and chemokines. Objective: We assessed the efficacy and safety of the standard of care (SoC) plus oral obefazimod (SoC plus AB...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Pedro Giavina-Bianchi, MD, PhD, Eric Cua, MD, Karine Risso, MD, Véronique Mondain, MD, Anaïs Vissian, MSc, Cécile Joie, MSc, Philippe Pouletty, MD, Paul Gineste, PharmD, Hartmut J. Ehrlich, MD, PhD, Jorge Kalil, MD, PhD
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: Elsevier 2023-11-01
Loạt:Journal of Allergy and Clinical Immunology: Global
Những chủ đề:
ABX464
obefazimod
miR-124
COVID-19
Truy cập trực tuyến:http://www.sciencedirect.com/science/article/pii/S2772829323000656

Internet

http://www.sciencedirect.com/science/article/pii/S2772829323000656

Những quyển sách tương tự